URGN
UroGen Pharma Ltd
43.20$
-0.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -53.5% | -86.2% | -98.4% | +65,450.0% | +307.2% | +34.0% | +28.5% | +9.3% | +21.4% | |
| – | – | -75.2% | +2,042.9% | +200.5% | -97.3% | +2,002.1% | +411.1% | +48.4% | +22.3% | -5.1% | +40.2% | |
| – | – | – | -56.8% | -108.9% | – | +59,844.4% | +297.5% | +32.2% | +29.4% | +11.1% | +19.4% | |
| – | +162.4% | -2.2% | +81.8% | +97.5% | +33.5% | -4.0% | +0.7% | +11.0% | -13.8% | +25.3% | +17.4% | |
| – | +112.9% | +238.6% | +37.3% | +349.1% | +52.1% | +49.9% | -55.7% | +107.4% | +9.1% | +34.1% | +28.0% | |
| – | +184.9% | +34.6% | +64.7% | +178.1% | +43.1% | +25.6% | -1.7% | +0.4% | +2.3% | +28.4% | +24.6% | |
| – | – | – | -2,600.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +1,193.3% | +374.9% | -51.6% | +74.4% | -14.9% | +170.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | – | +557.9% | -3,792.8% | – | -57.1% | +21.1% | +123.4% | -27.8% | -97.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -2,052.8% | – | – | – | – | – | – | – | – |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.